Five Oral Presentations On Clinical Experience With NanoKnife® System Featured At Society Of Interventional Radiology Conference

AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced oral presentations on NanoKnife ® System clinical experience took place at the Society of Interventional Radiology (SIR) 2012 Annual Scientific Meeting, March 24-29, 2012, in San Francisco, Calif.

An oral presentation titled “A prospective, multicenter phase II clinical trial using irreversible electroporation for the treatment of early stage HCC,” was given March 28, 2012. The authors of this Company-sponsored European study included Professors Riccardo Lencioni and Laura Crocetti of the University of Pisa, Pisa, Italy; Francesco Izzo of Istituto Nazionale Tumori – Fondazione Pascale, Naples, Italy; Valerie Vilgrain and Mohamed Abdel-Rehim of Hopital Beaujon, Paris, France; Jens Ricke and Maciej Pech of Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin, Magdeburg, Germany; Jordi Bruix and Luis Bianchi of the Hospital Clinic i Provincial de Barcelona (BCLC), Barcelona, Spain.

The trial is a phase II prospective, multicenter clinical study to evaluate the efficacy and safety of the NanoKnife System as a first-line treatment for early-stage hepatocellular carcinoma (HCC), the most common form of liver cancer. It is registered with www.ClinicalTrials.gov as number NCT01078415.

The following retrospective data analyses also were presented at SIR’s 2012 Annual Scientific Meeting.

An oral presentation titled “Downstaging locally advanced pancreatic adenocarcinoma (LAPC) with vascular encasement using percutaneous irreversible electroporation (IRE),” was given March 27 2012. The authors included Doctors Govindarajan Narayanan, Geetika Arora, Katuska Barbery, Tatiana Froud, Alan Livingstone, Dido Franceschi, Peter Hosein, Caio Rocha Lima, and Jose Yrizarry of the University of Miami, Miami, Fla.

Eight patients with biopsy-proven pancreatic cancer underwent percutaneous ablation of pancreatic tumors using the NanoKnife System. Imaging demonstrated intact veins in all patients’ treatment zones immediately, and 24-hours, after the procedure. Complications included spontaneous pneumothorax during anesthesia in one case and pancreatitis in one case. Both recovered completely. No mortalities occurred within 30 days. Follow up was conducted with each patient in the months after the procedure. This analysis also was the subject of a press release issued by SIR regarding the conference, as well as a press event hosted by the organization on March 26, 2012.

If you liked this article you might like

Endo international, AngioDynamics Lead Biotech Movers

As Economic Danger Looms, Will Entrepreneurs Come to the Rescue?

5 Stocks Everyone Hates -- but You Should Love

AngioDynamics (ANGO) Strong On High Relative Volume Today

5 Hated Earnings Stocks You Should Love